1. Home
  2. MIST vs KUKE Comparison

MIST vs KUKE Comparison

Compare MIST & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIST
  • KUKE
  • Stock Information
  • Founded
  • MIST 2003
  • KUKE 2002
  • Country
  • MIST Canada
  • KUKE China
  • Employees
  • MIST N/A
  • KUKE N/A
  • Industry
  • MIST Biotechnology: Pharmaceutical Preparations
  • KUKE Other Consumer Services
  • Sector
  • MIST Health Care
  • KUKE Real Estate
  • Exchange
  • MIST Nasdaq
  • KUKE Nasdaq
  • Market Cap
  • MIST 81.5M
  • KUKE 49.8M
  • IPO Year
  • MIST N/A
  • KUKE 2021
  • Fundamental
  • Price
  • MIST $1.43
  • KUKE $0.90
  • Analyst Decision
  • MIST Strong Buy
  • KUKE
  • Analyst Count
  • MIST 3
  • KUKE 0
  • Target Price
  • MIST $13.00
  • KUKE N/A
  • AVG Volume (30 Days)
  • MIST 177.8K
  • KUKE 834.1K
  • Earning Date
  • MIST 11-11-2024
  • KUKE 11-05-2024
  • Dividend Yield
  • MIST N/A
  • KUKE N/A
  • EPS Growth
  • MIST N/A
  • KUKE N/A
  • EPS
  • MIST N/A
  • KUKE N/A
  • Revenue
  • MIST N/A
  • KUKE $14,784,158.00
  • Revenue This Year
  • MIST N/A
  • KUKE N/A
  • Revenue Next Year
  • MIST N/A
  • KUKE N/A
  • P/E Ratio
  • MIST N/A
  • KUKE N/A
  • Revenue Growth
  • MIST N/A
  • KUKE N/A
  • 52 Week Low
  • MIST $1.12
  • KUKE $0.47
  • 52 Week High
  • MIST $3.52
  • KUKE $4.07
  • Technical
  • Relative Strength Index (RSI)
  • MIST 42.50
  • KUKE 56.06
  • Support Level
  • MIST $1.41
  • KUKE $0.47
  • Resistance Level
  • MIST $1.53
  • KUKE $1.00
  • Average True Range (ATR)
  • MIST 0.07
  • KUKE 0.16
  • MACD
  • MIST -0.01
  • KUKE 0.03
  • Stochastic Oscillator
  • MIST 26.96
  • KUKE 84.92

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

About KUKE Kuke Music Holding Limited

Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.

Share on Social Networks: